The latest update is out from CureVac ( (CVAC) ).
On March 27, 2025, CureVac announced a favorable decision from the European Patent Office in a patent litigation against BioNTech SE, confirming the validity of CureVac’s patent EP 3 708 668 B1 in an amended form. This decision is a significant milestone in the ongoing patent dispute involving six intellectual property rights and highlights CureVac’s pioneering role in mRNA innovation. An infringement hearing is scheduled for July 1, 2025, which could lead to damage assessments if the patent is found infringed. The ruling strengthens CureVac’s position in the mRNA technology sector and underscores its contributions to COVID-19 vaccine development.
More about CureVac
CureVac is a global biopharmaceutical company specializing in messenger RNA (mRNA) technology, with over 20 years of expertise. The company develops transformative medicines using optimized mRNA to instruct the human body to produce proteins for fighting diseases. CureVac collaborates with GSK to develop vaccines for infectious diseases and has a clinical pipeline in vaccines, cancer therapies, antibody therapies, and rare disease treatments. Headquartered in Tübingen, Germany, CureVac employs over 1,100 people across Europe and the U.S.
YTD Price Performance: -17.39%
Average Trading Volume: 804,176
Technical Sentiment Signal: Strong Buy
Current Market Cap: $639.3M
For an in-depth examination of CVAC stock, go to TipRanks’ Stock Analysis page.